News
- Anagram Therapeutics Announces Initiation of Clinical Study of ANG003 in People with Cystic FibrosisSEPTEMBER 27, 2023
- Anagram Therapeutics Appoints Three Industry Veterans to Leadership Team, Focused on Accelerating the Company’s Pipeline of Orally Delivered Enzymes for Rare DiseasesAPRIL 20, 2023
- Anagram Therapeutics Launches to Advance Orally Delivered Enzymes to Treat Malabsorption Syndromes and Nutrient Metabolism DisordersAPRIL 4, 2023
